TY - JOUR
T1 - Efficacy of mycobacterial components in the immunotherapy of mice with pulmonary tumor deposits
AU - Sukumar, S.
AU - Hunter, J. T.
AU - Yarkoni, E.
AU - Rapp, H. J.
AU - Zbar, B.
AU - Lederer, E.
PY - 1981/6
Y1 - 1981/6
N2 - The effectiveness of each of two mycobacterial components and a synthetic analog of one of them in the eradication of pulmonary deposits of intravenously injected syngeneic fibrosarcoma 1023 in C3H mice was studied. BCG cell walls (BCG CW), trehalose 6,6′-dimycolate (TDM) or 6,6′-di-0-2-tetradecyl, 3-hydroxyoctadecanoyl-α,α-trehalose (C76), a synthetic analog of TDM, was administered in emulsified form by three different routes: intraperitoneal, intradermal, or intravenous, 24 h after intravenous injection of 1023 tumor cells. The most effective form of therapy was TDM given by the intraperitoneal route; about 50% of treated animals were cured. Higher doses of BCG CW or C76 also led to a significant number of cures. Each agent caused a significant prolongation of survival time of the treated mice at two or more of the dosages tested; however, their routes of optimal activity varied.
AB - The effectiveness of each of two mycobacterial components and a synthetic analog of one of them in the eradication of pulmonary deposits of intravenously injected syngeneic fibrosarcoma 1023 in C3H mice was studied. BCG cell walls (BCG CW), trehalose 6,6′-dimycolate (TDM) or 6,6′-di-0-2-tetradecyl, 3-hydroxyoctadecanoyl-α,α-trehalose (C76), a synthetic analog of TDM, was administered in emulsified form by three different routes: intraperitoneal, intradermal, or intravenous, 24 h after intravenous injection of 1023 tumor cells. The most effective form of therapy was TDM given by the intraperitoneal route; about 50% of treated animals were cured. Higher doses of BCG CW or C76 also led to a significant number of cures. Each agent caused a significant prolongation of survival time of the treated mice at two or more of the dosages tested; however, their routes of optimal activity varied.
UR - http://www.scopus.com/inward/record.url?scp=0019403184&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0019403184&partnerID=8YFLogxK
U2 - 10.1007/BF00199263
DO - 10.1007/BF00199263
M3 - Article
AN - SCOPUS:0019403184
SN - 0340-7004
VL - 11
SP - 125
EP - 129
JO - Cancer Immunology Immunotherapy
JF - Cancer Immunology Immunotherapy
IS - 2
ER -